Vicore Pharma: Unlocking the potential of a new class of drugs, Angiotensin II type 2 receptor agonists, with transformative potential in idiopathic pulmonary fibrosis (IPF)

Company in Brief

Vicore Pharma is a clinical-stage biopharmaceutical company with a vision to transform the lives of patients where modulation of the AT2 (angiotensin II type 2) receptor can play a central role in halting and reversing disease pathology

Locations: Stockholm, Sweden, Cambridge, MA, USA & Copenhagen, Denmark
Employees: ~40 FTEs
Ticker: VICO, listed on the Nasdaq Stockholm exchange
Website: www.vicorepharma.com

Management Team

Strong leadership team with extensive industry experience.

Ahmed Mousa*
Chief Executive Officer

Mikael Nygård
Chief Operating Officer

Megan Richards
VP Investor Relations, Communications and Portfolio Strategy

Katrine Husum*
VP Program Management

Hans Jeppsson
Chief Financial Officer

Helen Barker
Chief Technology Officer

Christophe Giot*
VP Medical Affairs

Johanna Gräns
Head of Non-Clinical Development

Johan Raud*
Chief Scientific Officer

Jimmie Hofman*
Chief Business Officer

Karin Eklund Vanderpol
VP Regulatory Affairs

Lene Eskildsen
Head of Quality Assurance

Bernt van den Blink*
Chief Medical Officer

Nina Carlén
Chief Administrative Officer

Anne-Katrine Cohrt
VP Clinical Operations

Bertil Lindmark*
Senior Advisor

*Attending RIS

Board Members

Hans Schikan
Chairman. 25 years management experience in global pharmaceuticals (CEO of Prosensa & leading roles at Genzyme and Organon). Extensive board work in listed life science companies (Hansa Biopharma, Wilson Tx (acquired by Alexion), SOBI, Asceneuron, InteRNA and Therachon (acquired by Pfizer).

Jacob Gunterberg
Former partner at HealthCap with extensive experience from venture capital investment operations and corporate finance in life science. Extensive experience as board member in both private and publicly traded companies.

Heidi Hunter
More than 25 years of experience from leading positions in different roles within pharmaceutical development and commercialization. Leadership experience spans alliance management, investment risk mitigation, global clinical and commercial management, new business strategy development, product launch, and business sustainability.

Ann Barbier
Ann has more than 20 years of drug discovery and development experience in the pharmaceutical and biotech worlds. She has contributed to several approved drugs and has worked in the rare disease, neuropsychiatry and pulmonology fields.

Elisabeth Björk
More than 15 years of experience from clinical practice, academic research and management of drug development in big pharma as well as global commercial strategy and implementation across regions and therapy areas. Currently leading global late-stage development activities in Cardiovascular, Renal & Metabolism at AstraZeneca.

Peter Guenter
Peter brings nearly four decades of executive leadership in the global biopharmaceutical industry (CEO of Merck Healthcare, serving as a member of the Executive Board of Merck Group, CEO of Almirall, executive roles at Sanofi). Active board contributor across healthcare and private equity.

Yasir Al-Wakeel
Yasir is a seasoned executive, board member, and strategic advisor to biotech companies. He is currently the CEO of a genetic medicines company based in California and serves as an independent board member for Maxcyte. Yasir has had operational experience running finance and business development functions at both public and private biotech companies, and prior to that had senior roles in investment banking both as an equity analyst and in corporate finance.

Pipeline

Compound	Indication	Preclinical	Phase 1	Phase 2	Phase 3	Comments	Rights
Buloxibutid	IPF					Phase 2b ongoing (NCT06588686) Enrollment complete. Targeting topline readout in mid-2027	Global ex-Japan rights Japan: NIPPON SHINYAKU CO., LTD.
New ATRAGs	Multiple Indications					Preclinical studies	Fully-owned

Buloxibutid demonstrates clinically meaningful effect on lung function in IPF

Unprecedented clinical data with buloxibutid in IPF - Phase 2a AIR trial[1,2]



Note: Note: n=48 patients with 2-week FVC data. Observed values, no imputation. *p<0.05, **p<0.01, ***p<0.001; t-test versus expected untreated decline corresponding to -120 mL/24 weeks

References: [1] Noble et al. Eur Respir J. 2016 Jan; 47(1): 243–253, [2] Richeldi et al. Engl J Med 2014; 370:2071-2082

Development of a Synthetic Control Arm analysis to contextualize buloxibutid's effect in the AIR trial



A Synthetic Control Arm analysis demonstrates buloxibutid's robust treatment effect



The Monte Carlo approach demonstrates that in patients without significant differences in core baseline parameters, buloxibutid showed statistically significant treatment effect compared to control FVC distribution

Strong preclinical evidence for buloxibutid in pulmonary fibrosis

Buloxibutid is an oral, selective AT2R agonist that drives tissue repair via AEC2 precursor epithelial cells



Buloxibutid reduces TGFb1 and collagen in human IPF lung slices



Fibrosis reduction in humans IPF lung slices (PCLuS)

Dose-dependent reduction of TGFβ1 and Collagen-1a1 protein

Reference: Vicore data on file

Buloxibutid reduces fibrosis, collagen content and reverses vascular remodeling



Reference: Bruce et al. 2015, Rathinasabapathy et al. 2018, Tomling et al.2023

Vicore Presence at the ATS 2026 Congress

Buloxibutid ongoing global Phase 2b ASPIRE trial in IPF (NCT06588686)



ASPIRE

Primary Endpoint:
Change from baseline in FVC at 52 weeks

Key Secondary Endpoint:
Proportion of patients with disease progression at 52 weeks

[1]As nerandomilast is now approved in the United States, patients receiving stable background nerandomilast therapy will be eligible for enrollment in the trial, though this is anticipated to represent a small subset of the study population.

Check out our ASPIRE clinical trial booth at Clinical Trials Area, CT-3100

Oral and Poster Presentations

Buloxibutid Stabilizes and Improves Lung Function in Idiopathic Pulmonary Fibrosis and Elevates Plasma Mmp-13, Linking AT2 Receptor Activation in Alveolar Epithelial Type 2 Cells to Resolution of Fibrosis

- A110 CLOSING THE GAP: ADVANCES IN PULMONARY FIBROSIS
- Sunday, May 17, 2026
- 2:15 PM – 4:15 PM (EDT)
- West F3 (Level II, OCCC West Concourse)
- Poster Discussion Session (Poster Board #506)

Buloxibutid's Efficacy in the Phase 2a Air IPF Trial: Comparative Analysis of Baseline Characteristics of Indian Versus World Cohorts

- C103 THE NEXT FRONTIER OF THERAPY IN PULMONARY FIBROSIS
- Tuesday, May 19, 2026
- 2:15 PM – 4:15 PM (EDT)
- West F3 (Level II, OCCC West Concourse)
- Poster Discussion Session (Poster Board #522)

Microvascular Normalization and Fibrosis Regression by The Angiotensin II Type 2 Receptor Agonist Buloxibutid in Pulmonary Hypertension Associated With Interstitial Lung Disease

- D109 NOVEL INSIGHTS INTO PULMONARY VASCULAR DISEASES
- Wednesday, May 20, 2026
- 11:00 AM – 1:00 PM (EDT)
- W414AB (Level IV, OCCC West Concourse)
- Poster Discussion Session (Poster Board #902)

Thank you to patients and their caregivers for supporting our trials. We recognize your contribution to research.

RIS Respiratory Innovation Summit
ATS 2026

vicore pharma